Clinical trials: Lung Cancer, Small Cell
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma
Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer
This research study is examining the benefit of a novel radiation planning approach on the likelihood of developing severe esophagitis (irritation and inflammation of the esophagus) during the course of radiation therapy with…
- Trial name
- NCT02394548
- Testing
- Contralateral Esophageal Sparing Technique (CEST)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Small Cell Lung Cancer
Study of Pemetrexed and Carboplatin Compared With Etoposide Carboplatin to Treat Extensive-Stage Small Cell Lung Cancer
This study is a Phase 3, global, multi-center, open-label study of patients with extensive-stage small cell lung cancer. Eligible patients will be randomly assigned to receive either pemetrexed plus carboplatin or etoposide plus…
- Trial name
- NCT00363415
- Testing
- pemetrexed, etoposide, carboplatin
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 908 people
- Sponsor
- Eli Lilly and Company
Solid Tumors, Head and Neck Carcinoma
Milademetan in Advanced/Metastatic Solid Tumors
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that…
- Conditions
- Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma
- Trial name
- NCT05012397
- Testing
- RAIN-32
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Rain Oncology Inc
Lung Cancer - Non Small Cell
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
- Trial name
- NCT01471197
- Testing
- Ipilimumab, Pemetrexed
- Where
- 13 sites in United States, Belgium and 3 more
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Bladder Cancer, Cervical Cancer
Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
RATIONALE: Stop-smoking plans, including counseling and nicotine replacement therapy, may help smokers quit smoking. It is not yet known whether counseling and the nicotine lozenge is more effective than counseling and the…
- Conditions
- Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT00365508
- Testing
- nicotine lozenge, nicotine patch
- Where
- 10 sites in United States
- Volunteers
- 642 people
- Sponsor
- Fox Chase Cancer Center
Non-small Cell Lung Cancer
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors
This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.
- Trial name
- RADIANT (NCT00373425)
- Testing
- Erlotinib
- Where
- 295 sites in United States, Argentina and 17 more
- Volunteers
- 1,252 people
- Sponsor
- OSI Pharmaceuticals
Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer.
- Trial name
- NCT03087708
- Testing
- Naloxegol, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 660 sites in United States
- Volunteers
- 50 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Carcinoma, Non-Small-Cell Lung, Adenocarcinoma
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
To investigate the efficacy and safety of BIBW 2992 compared to standard first-line chemotherapy in patients with stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation
- Trial name
- NCT01121393
- Testing
- Gemcitabine+Cisplatin, BIBW 2992
- Where
- 36 sites in China, South Korea and 1 more
- Volunteers
- 364 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Pharmacological Ascorbate for Lung Cancer
This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care treatment of non-small cell lung cancer (NSCLC) in adults.
- Trial name
- NCT02420314
- Testing
- Paclitaxel, Carboplatin, Ascorbic Acid
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Joseph J. Cullen, MD, FACS
Non-Small Cell Lung Cancer
Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC
This is a multicenter randomized phase II to determine if the administration of standard platinum-based chemotherapy before MK-3475 in with Chemotherapy naive stage IV Non-small Cell Lung Cancer (NSCLC) will improve the overall…
- Trial name
- NCT02591615
- Testing
- MK-3475, Carboplatin, Paclitaxel
- Where
- 11 sites in United States
- Volunteers
- 91 people
- Sponsor
- Alliance Foundation Trials, LLC.
Advanced Malignancies, Metastatic Cancer
A Study of INCAGN01876 in Participants With Advanced or Metastatic Solid Tumors
This was an open-label, non-randomized Phase 1/2 safety study of INCAGN01876 in participants with advanced or metastatic solid tumors that was conducted in 2 parts.
- Trial name
- NCT02697591
- Testing
- INCAGN01876
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Incyte Biosciences International Sàrl
Non-Small-Cell Lung Cancer
Pemetrexed and Cisplatin Treatment Before Surgery in Non Small Cell Lung Cancer
To determine the response to this regimen for therapy prior surgery in patients with locally advanced disease or metastatic disease.
- Trial name
- NCT00259285
- Testing
- pemetrexed, cisplatin
- Where
- 6 sites in Spain
- Volunteers
- 10 people
- Sponsor
- Eli Lilly and Company
Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
This phase Ib/II trial studies the side effects and best dose of plinabulin in combination with radiation therapy and immunotherapy in patients with select cancers that have spread to other places in the body (advanced) after…
- Conditions
- Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT04902040
- Testing
- Atezolizumab, Avelumab, Durvalumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Non-small-cell Lung
A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer
It is generally accepted that the presence of chronically hypoxic cells, or tumor cells which do not receive enough oxygen as a result of tumor growth, may be an important cause of resistance to radiation therapy (RT) and…
- Trial name
- NCT00983307
- Testing
- Erlotinib, Hypofractionated Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
This research study is being done to assess the safety and tolerability of study drugs, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) and nivolumab in subjects with small cell lung cancer or advanced or inoperable neuroendocrine tumor…
- Trial name
- NCT03325816
- Testing
- Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Georgetown University
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Pancreatic Cancer, Colorectal Cancer
Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer
A multi-center Phase 1b/2 study testing the combination of AMG 820 and pembrolizumab in subjects with select advanced solid tumors.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02713529
- Testing
- AMG820 and pembrolizumab
- Where
- 15 sites in United States, Australia and 4 more
- Volunteers
- 117 people
- Sponsor
- AmMax Bio, Inc.
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Non Small Cell Lung Cancer
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
The purpose of this study is to evaluate the progression-free survival (PFS) rate at 6 months of ramucirumab administered in combination with paclitaxel and carboplatin as first-line therapy for Stage IIIB or IV non-small cell…
- Trial name
- NCT00735696
- Testing
- Ramucirumab, Paclitaxel, Carboplatin
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.